stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Repligen Corporation

United States · NASDAQ: RGEN · Market cap: · P/E: · P/S:

Repligen sells the equipment, filters, and ingredients that biopharma companies use to manufacture biologic drugs.

Repligen is a supplier to the biotech industry. It doesn't discover new medicines itself and doesn't sell drugs to patients. Instead, it makes the gear and ingredients that other companies need to turn living cells into medicine. The customer is almost always a biopharmaceutical manufacturer, and what they are buying is a way to make their own production faster, purer, and cheaper.

Repligen Corporation (RGEN) Filtration products for bioprocessing: line art illustration of A hollow-fiber filtration cartridge with its cylindrical housing and port fittings
Filtration products
Repligen's filtration products are used to separate and purify fluids in making biologic medicines.

Its most important products are filtration systems and a set of tools used to capture and purify proteins. Consider the problem: a bioreactor full of cells makes a soup that contains the drug you want plus a lot of junk you don't. Repligen sells the filters and separation products that pull the wanted molecule out and throw the junk away. It also sells a substance called protein A that helps capture antibodies, plus cell-culture ingredients and equipment for a technique called alternating tangential flow, which keeps cells alive and happy while they grow. If you're sensing a theme, it's that Repligen profits from every stage of the production line rather than betting on any single drug. The business is tied to the drug industry's most popular category: antibodies and other biologic medicines. When a big drugmaker needs more manufacturing capacity, or a new wave of biosimilar copies of older antibody drugs gets approved, demand for Repligen's products tends to rise. Its customers include Sartorius and other large life-science suppliers, though the company's revenue is heavily concentrated in a small number of big customers. That concentration is a real risk: losing one account or a slowdown in a customer's manufacturing plans can dent results quickly.


The company isn't cheap to run, but the economics are attractive when demand is strong. It spends heavily on research and has grown partly by buying smaller businesses to add products to its catalog, which is how it broadened from filtration into cell culture and purification. Free cash flow goes into product development, acquisitions, and buying back shares. When the pandemic boosted bioprocessing demand, Repligen's sales surged, then cooled as customers worked through stockpiles. That swing is a useful reminder of the business's real vulnerability: it follows the capital spending mood of the drug industry, which can be generous one year and cautious the next.

Saved answer · last researched 16 Nov 2026